NCT06846671 2026-03-19
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
5 trialsNCT02135133 2026-03-17
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Phase 2 Completed
NCT07218341 2026-02-10
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 4 Not yet recruiting
NCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02787369 2026-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting